2017-03-16,Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara
2017-03-06,Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients
2017-01-07,Mast Therapeutics And Savara Sign Merger Agreement
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-06,Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction
2016-11-21,How to Trade These Most Active Stocks -- LifeLock, Tyson Foods and More
2016-11-21,Mast Therapeutics Provides Update On Strategic Direction
2016-11-03,Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF) Published In Journal Of Clinical Investigation
2016-11-01,Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call
2016-10-31,Research Reports On Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, And Clovis Oncology
2016-10-17,Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001
2016-10-13,Mast Therapeutics To Present At 2016 BIO Investor Forum On October 19th
2016-09-26,Mast Therapeutics Provides Business Update
2016-09-21,5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid
2016-09-20,Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease
2016-09-06,Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care
2016-09-01,Mast Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference On September 13th
2016-08-22,MSTX April 2017 Options Begin Trading
2016-08-08,Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health
2016-08-03,Mast Therapeutics Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer
2016-08-02,Mast Therapeutics To Present At 36th Annual Canaccord Genuity Growth Conference On August 10
2016-08-01,Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network
2016-06-08,Mast Therapeutics Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer
2016-05-23,Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At European Society Of Cardiology 3rd World Congress On Acute Heart Failure
2016-05-16,Positive Interim Results From Second Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Presented At American Thoracic Society International Conference
2016-05-12,Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City
2016-04-13,Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network
2016-04-04,Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo
2016-03-01,Mast Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference On March 7th
2016-02-29,Mast Announces Amendment To Loan And Security Agreement With Hercules Capital
2016-02-22,Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis
2016-02-16,Mast Therapeutics Closes $8 Million Public Offering
2016-02-10,Mast Therapeutics Announces Pricing Of Underwritten Public Offering
2016-02-09,Mast Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
2016-02-02,Mast Therapeutics To Present At 2016 BIO CEO & Investor Conference On February 8th
2016-02-01,Mast Therapeutics' AIR001 Selected By The Heart Failure Clinical Research Network For Evaluation In A 100-Patient Multicenter Phase 2 Study
2016-02-01,Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic
2016-01-07,Mast Therapeutics Provides Business Update
2015-11-24,Mast Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-16,Vepoloxamer Data Selected For Presentation At 57th Annual American Society Of Hematology (ASH) Meeting
2015-11-09,Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions
2015-11-09,Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board Of Directors
2015-11-02,Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors
2015-10-29,Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call
2015-10-26,Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure
2015-10-13,BASF to Develop a High Purity Poloxamer for Mast Therapeutics
2015-09-30,Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital
2015-09-29,3 Stocks Under $10 to Trade for Big Breakouts
2015-09-28,Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting
2015-09-23,Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015
2015-08-06,Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call
2015-05-28,Mast Therapeutics Announces Change In Board Of Directors
2015-05-26,Mast Therapeutics Announces Initiation Of EPIC-E Study
2015-04-21,Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark
2015-04-09,Mast To Present New Data Supporting Vepoloxamer (MST-188) In Sickle Cell Disease At 9th Annual Sickle Cell Disease Research And Education Symposium And 38th National Sickle Cell Disease Scientific Meeting
2015-03-23,Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure
2015-03-02,Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure
2015-02-24,Mast Therapeutics To Present At Cowen And Company's 35th Annual Healthcare Conference On March 2nd
2015-02-13,Biotech Stock Mailbag: MannKind, Mast Therapeutics, Bluebird
2015-02-11,Mast Therapeutics Announces New Data Supporting Vepoloxamer In Embolic Stroke
2015-02-04,Mast Therapeutics Announces Initiation Of Phase 2a Studies Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
2015-02-03,Mast Therapeutics To Present At 17th Annual BIO CEO & Investor Conference On February 9th
2015-01-24,Mast Therapeutics Announces Management Change
2015-01-07,Mast Therapeutics To Present At 2015 Biotech Showcase Conference On January 12th
2015-01-05,Mast Therapeutics Provides Update On Epic Study Enrollment And 2015 Milestones
2014-12-30,Mast Therapeutics To Host Corporate Conference Call
2014-12-09,Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure
2014-11-26,Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd
2014-11-20,Two Small-Cap Biotechnology Gems
2014-11-19,New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference
2014-11-17,Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference
2014-11-13,Mast Therapeutics Announces Closing Of Underwritten Public Offering
2014-11-06,Mast Therapeutics Announces Pricing Of Underwritten Public Offering
2014-11-05,Mast Therapeutics Announces Underwritten Public Offering
2014-10-02,Mast Therapeutics Announces Appointment Of Chief Medical Officer
2014-09-08,Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
2014-09-02,Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
2014-08-29,Mast Therapeutics Announces Management Change
2014-08-07,Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
2014-06-20,4 Biotech Stocks Under $10 to Watch for Breakout Trades
2014-06-19,Mast Announces Appointment Of Howard C. Dittrich M.D. To Board Of Directors
2014-06-16,Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-19,Interesting MSTX Put And Call Options For January 2015
2014-04-14,Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease
2014-03-26,A Small-Cap Biotech Stock With Promise: MSTX
2014-03-26,Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
2014-03-11,Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
2014-03-06,5 Stocks Under $10 Set to Soar
2014-02-27,Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
2014-02-25,Interesting MSTX Call Options For October 18th
2014-02-25,Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
2014-02-24,Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
2014-02-18,Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
2014-02-10,Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
2014-01-23,Interesting MSTX Call Options For March 22nd
2014-01-08,Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
2014-01-07,Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14
2014-01-06,Mast Therapeutics Announces Positive Data In Model Of Heart Failure
2013-11-26,Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3
2013-11-13,FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
2013-10-30,5 Stocks Under $10 on the Verge of Breakouts
2013-10-01,Mast Therapeutics To Present At The 12th Annual BIO Investor Forum On October 8
2013-09-30,Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2
2013-09-06,Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
2013-09-03,Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
2013-07-23,Mast Therapeutics Reports Results From Clinical QT Study Of MST-188
2013-07-19,2 Biotech Stocks Under $10 to Watch
2013-07-03,Mast Therapeutics To Present At The JMP Securities Healthcare Conference On July 9
2013-06-14,Mast Therapeutics Prices Public Offering Of Units
2013-04-17,Mast Therapeutics Presents MST-188 Data At 7Th Annual Sickle Cell Disease Research And Educational Symposium
2013-03-28,Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
2013-03-25,European Commission Designates MST-188 As An Orphan Medicinal Product
,
,
